

Anti-NCAM1/CD56 Antibody (Lorvotuzumab)

Introduction

Lorvotuzumab is a humanized monoclonal antibody derived from mouse monoclonal antibodies and modified by genetic engineering. Its composition includes the antibody structure of the IgG1 subtype. The mechanism of action of Lorvotuzumab is to inhibit the growth and spread of tumor cells by targeting the CD56 molecule (neural cell adhesion molecule, NCAM) and blocking its signaling pathway. It is mainly used to treat cancers that express CD56, such as small cell lung cancer and multiple myeloma.

Product parameters

Alternative Names	hLorvotuzumab, IMGN901
Target Accession	-
Target	NCAM1/CD56
CAS number	339306-30-8
Molecular Weight	145.5 kDa
Host	CHO
Reactivity	Human
Conjugation	Unconjugated
Form	Liquid
Concentration	1 mg/mL
Buffer System	100 mM Pro 20 mM Arg pH 5.0.
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	-
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 µM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

■ Note

1. This product is for scientific research use only.



APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

